Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$139.81

-1.09 (-0.77%)

04:55
10/23/19
10/23
04:55
10/23/19
04:55

Sage Therapeutics management to meet with Jefferies

Meetings to be held in New York on October 22 and in Boston on October 23 hosted by Jefferies.

  • 23

    Oct

  • 12

    Nov

SAGE Sage Therapeutics
$139.81

-1.09 (-0.77%)

10/03/19
10/03/19
NO CHANGE

Sage Therapeutics participates in a conference call with JPMorgan
Large Cap Biotechnology Analyst Kasimov holds a conference call with CEO Jonas, CFO Iguchi and CSO Robichaud on October 3 at 10 am hosted by JPMorgan. Reference Link
10/17/19
JEFF
10/17/19
NO CHANGE
Target $195
JEFF
Buy
Sage Therapeutics recent selloff a buying opportunity, says Jefferies
Jefferies analyst Michael Yee says recent market weakness has created a buying opportunity for shares of Sage Therapeutics. The analyst remains bullish ahead of the company's Phase III depression data. Positive data could push Sage's stock past $200 versus of downside of $80-$100 on negative results, Yee tells investors in a research note. Positive data could open up a $4B-$6B sales opportunity and also increase the likelihood of a Sage Therapeutics takeover, Yee adds. He keeps a Buy rating on the shares with a $195 price target.
10/22/19
PIPR
10/22/19
NO CHANGE
Target $206
PIPR
Overweight
Piper bullish on Sage Therapeutics into major depressive disorder data
Enrollment in Sage Therapeutics' pivotal SAGE-217 major depressive disorder Mountain trial completed in September and top-line data could be announced in December, Piper Jaffray analyst Danielle Brill tells investors in a research note. The analyst believe SAGE-217 will be an approvable drug with positive results, and sees 30%-40% upside for the stock in this scenario. With that said, over 90% of Sage's value is derived from SAGE-217, so downside on negative data would also likely be significant, adds the analyst. However, she thinks would be capped at 35%-40% given the other ongoing trials that could support registration. "We know investors are avoiding binary risk, but we're believers in 217 and are still bullish into the data," concludes Brill, who keeps an Overweight rating on Sage Therapeutics with a $206 price target.

TODAY'S FREE FLY STORIES

BXRX

Baudax Bio

$4.66

-0.59 (-11.24%)

07:24
11/22/19
11/22
07:24
11/22/19
07:24
Initiation
Baudax Bio initiated  »

Baudax Bio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$53.89

1.41 (2.69%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Biohaven Pharmaceutical initiated  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$56.84

0.455 (0.81%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Bristol-Myers initiated  »

Bristol-Myers resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ENR

Energizer

$49.05

1.33 (2.79%)

07:22
11/22/19
11/22
07:22
11/22/19
07:22
Recommendations
Energizer analyst commentary  »

Energizer Analyst Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,734.99

-10.51 (-0.60%)

, MSFT

Microsoft

$149.46

-0.14 (-0.09%)

07:20
11/22/19
11/22
07:20
11/22/19
07:20
Periodicals
Amazon suit to likely delay start of Pentagon technology program, Bloomberg says »

Amazon (AMZN) could…

AMZN

Amazon.com

$1,734.99

-10.51 (-0.60%)

MSFT

Microsoft

$149.46

-0.14 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

ABCB

Ameris Bancorp

$42.81

-0.4 (-0.93%)

07:19
11/22/19
11/22
07:19
11/22/19
07:19
Recommendations
Ameris Bancorp analyst commentary  »

Ameris Bancorp subpoena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BWEN

Broadwind Energy

$1.44

-0.06 (-4.00%)

07:18
11/22/19
11/22
07:18
11/22/19
07:18
Hot Stocks
Broadwind Energy receives first solar market order »

Broadwind Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$1.51

-0.06 (-3.83%)

07:18
11/22/19
11/22
07:18
11/22/19
07:18
Hot Stocks
Astrotech says 1st Detect sells TRACER 1000s to shipping & logistics company »

Astrotech Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGS

Medigus

$1.76

(0.00%)

07:17
11/22/19
11/22
07:17
11/22/19
07:17
Hot Stocks
Medigus receives $1.2M payment as part of MUSE agreement in China »

Medigus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:16
11/22/19
11/22
07:16
11/22/19
07:16
Hot Stocks
Breaking Hot Stocks news story on Destination XL »

Destination XL to close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

T

AT&T

$37.59

0.415 (1.12%)

07:15
11/22/19
11/22
07:15
11/22/19
07:15
Recommendations
AT&T analyst commentary  »

AT&T near-term short…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:15
11/22/19
11/22
07:15
11/22/19
07:15
Hot Stocks
Destination XL expects FY19 free cash flow to be breakeven »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

ANIX

Anixa Biosciences

$3.50

-0.11 (-3.05%)

07:13
11/22/19
11/22
07:13
11/22/19
07:13
Hot Stocks
Anixa Biosciences announces Cchek study collaboration with UCA »

Anixa Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:13
11/22/19
11/22
07:13
11/22/19
07:13
Earnings
Destination XL reports Q3 adj. EPS (8c) vs. (2c) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:11
11/22/19
11/22
07:11
11/22/19
07:11
Hot Stocks
Destination XL announces Ujjwal Dhoot as chief digital officer »

Destination XL announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

TREE

LendingTree

$365.30

-5.29 (-1.43%)

07:11
11/22/19
11/22
07:11
11/22/19
07:11
Initiation
LendingTree initiated  »

JPMorgan starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ENR

Energizer

$49.05

1.33 (2.79%)

07:09
11/22/19
11/22
07:09
11/22/19
07:09
Hot Stocks
Energizer targets 'top-line growth above category' in FY20-FY22 »

Also targets adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$2.85

-0.05 (-1.72%)

07:08
11/22/19
11/22
07:08
11/22/19
07:08
Hot Stocks
Neovasc says Reducer featured during therapy development program in Coburg »

Neovasc announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$60.22

0.85 (1.43%)

07:08
11/22/19
11/22
07:08
11/22/19
07:08
Recommendations
ConocoPhillips analyst commentary  »

ConocoPhillips price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJM

J.M. Smucker

$104.40

-1.15 (-1.09%)

07:08
11/22/19
11/22
07:08
11/22/19
07:08
Hot Stocks
J.M. Smucker CEO says Q2 sales performance did not meet expectations »

"While our second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

LHCG

LHC Group

$131.10

0.57 (0.44%)

07:06
11/22/19
11/22
07:06
11/22/19
07:06
Hot Stocks
LHC Group, Texas Health, Methodist Health purchase Healthcare Resources »

LHC Group, Texas Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

SJM

J.M. Smucker

$104.40

-1.15 (-1.09%)

07:06
11/22/19
11/22
07:06
11/22/19
07:06
Earnings
J.M. Smucker cuts FY20 adj. EPS view to $8.10-$8.30 from $8.35-$8.55 »

Consensus $8.27. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

RMR

RMR Group

$48.26

0.02 (0.04%)

07:06
11/22/19
11/22
07:06
11/22/19
07:06
Earnings
RMR Group reports Q4 adj. EPS 59c, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

NAVB

Navidea

$0.71

-0.0322 (-4.34%)

07:05
11/22/19
11/22
07:05
11/22/19
07:05
Initiation
Navidea initiated  »

Navidea initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
11/22/19
11/22
07:05
11/22/19
07:05
General news
FX Update: The dollar has been trading steady-to-firmer »

FX Update: The dollar has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.